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Abstract 
Multiple myeloma (MM) remains an essentially incurable hematologic malignancy originating from 
clonal plasma cells. This study evaluated the usefulness of the radiotracers 11C-methionine (MET) 
and 18F-2`-deoxy-2`-fluorodeoxyglucose (FDG) for staging and re-staging in MM.  
43 patients with MM underwent both MET- and FDG-PET/CT for staging or re-staging within 3±2 
days. Scans were compared on a patient and on a lesion basis. Tracer uptake was correlated with 
the degree of bone marrow (BM) involvement and standard clinical parameters of disease activity. 
Additionally, BM samples were stained for L-type amino acid transporter 1 (LAT1) expression in 
15 patients. MET-PET detected focal lesions (FL) in 39/43 subjects (90.7%), whereas 10 patients 
were missed in FDG-PET/CT (detection rate, 33/43; 76.7%; p<0.05). MET depicted more FL in 
28/43 patients (65.1%; p<0.001), whereas in the remainder (34.9%, n=15) both tracers yielded 
comparable results. LAT1 was highly expressed on the cell surface of myeloma cells. Both FDG and 
MET uptake correlated significantly with biopsy-proven BM involvement (p<0.001), with MET 
demonstrating a stronger correlation (SUVmean, r=0.9 vs r=0.6; SUVmax, r=0.88 vs r=0.58). Ab-
normal beta-2-microglobulin and free light chain levels correlated with the presence of focal in-
tramedullary lesions detected in MET- or FDG-PET/CT (MET, p=0.006 and p=0.01, respectively; 
FDG, p=0.02 and p=0.01). MET appears to be superior to FDG for staging and re-staging of both 
intra- and extramedullary MM lesions. Tracer uptake correlates with BM involvement, β2m and 
FLC levels and appears to be a more accurate marker of tumor burden and disease activity. 
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Introduction 
Multiple myeloma (MM) accounts for approxi-
mately 1% of all cancers and around 10% of hemato-
logical malignancies [1, 2]. Although MM essentially 
remains incurable, overall survival has improved over 
the last decade due to availability of various novel 
drugs and treatment options. Several studies have 
demonstrated the utility of molecular imaging using 
positron emission tomography (PET) and the radio-
labeled glucose analog 18F-2`-deoxy-2`-fluorodeoxy-
glucose (FDG) for diagnosis, staging and estimation of 
prognosis [3-7]. However, limitations of FDG include 
lack of sensitivity and specificity, e.g. in cases with 
diffuse bone marrow infiltration (false negative) or 
with inflammatory lesions (false positive) [8]. We 
previously reported a significantly higher retention of 
the radiolabelled amino acid L-methyl-[11C]- 
methionine (MET) in well characterized myeloma cell 








feasibility of monitoring very early treatment re-
sponse with MET in vitro and in vivo. Furthermore, 
MET-uptake could be linked to underlying tumor 
biology by demonstrating an association with intra-
cellular Ig light chain levels and treatment-induced 
changes in CD138 cell surface expression [9, 10]. First 
human studies also suggested a potential for MET in 
MM diagnosis [11, 12]. This study aimed at further 
validation of MET as superior radiotracer for func-
tional imaging of MM in comparison to FDG. 
Materials and Methods 
This prospective study was approved by the lo-
cal ethics committee of the University of Würzburg. 
All patients gave written informed consent to FDG- 
and MET- PET/computed tomography (CT) imaging. 
MET was administered under the conditions of the 
pharmaceutical law (German Medicinal Products Act, 
AMG §13 2b) according to the German law and in 
accordance with the responsible regulator bodies 
(Regierung von Oberfranken). 
Subjects 
43 patients (24 males, 19 females, age 39-82 y, 
mean 61±9 y) with newly diagnosed (n=11) or a his-
tory of (n=32) MM were prospectively enrolled. All 
patients with longer-standing disease had been 
pre-treated with a number of various chemothera-
peutic drug regimens including novel agents such as 
bortezomib, lenalidomide and others. 25/32 
pre-treated subjects had undergone autologous stem 
cell transplantation (SCT). At the time point of 
PET/CT scanning, serum free immunoglobulin light 
chains (FLC; (all patients) and the M gradient (40/43) 
were recorded. Serum chemistry including lactate 
dehydrogenase (LDH), albumin, creatinine (all pa-
tients) and β2-microglobulin (40/43 patients) were 
obtained. Information on degree of myeloma bone 
marrow (BM) infiltration based on iliac crest biopsy 
was present in 31/43 patients. Additionally, inter-
phase molecular cytogenetics based on fluorescence in 
situ hybridization (FISH) were available in 33/43 pa-
tients. Presence of del(17p), t(4;14), t(14;16), t(14;20) 
and chromosome 1 abnormalities were considered as 
high-risk, whereas all other karyotypes were classi-
fied as standard risk. 
PET/CT 
FDG and MET were synthesized in house with a 
16 MeV Cyclotron (GE PETtrace 6; GE Healthcare, 
Milwaukee, USA). PET/CT was performed on a 
PET/CT scanner (Siemens Biograph mCT 64, Sie-
mens, Knoxville, USA) within a mean interval of 3±2 
days between scans. 
FDG (299 ± 22 MBq) and MET (755 ± 82 MBq) 
were injected intravenously. CT scans were acquired 
after 60 (FDG) or 20 min (MET), respectively, using 
contrast-enhanced (FDG; depending on kidney func-
tion; dose modulation with a quality reference of 210 
mAs) or low-dose spiral CT (80 mAs, 120 kV, a 512 × 
512 matrix, 5 mm slice thickness, increment of 30 
mm/s, rotation time of 0.5 s, and pitch index of 0.8) 
including the skull to the proximal thighs. Consecu-
tively, PET emission data were acquired in 3D-mode 
with a 200 × 200 matrix with 2 min emission time per 
bed position. After decay and scatter correction, PET 
data were reconstructed iteratively with attenuation 
correction using a dedicated software (HD. PET, Sie-
mens Esoft, Erlangen, Germany). 
Image analysis 
For FDG, criteria to define lesions as 
PET-positive were applied according to Zamagni et al. 
[13], for MET, lesions were visually determined as 
focally increased tracer retention as compared to sur-
rounding normal tissue or contralateral structures. 
Presence and number of intra- and extramedullary 
(EMD) disease as well as location of lesions were rec-
orded. Analysis both on a patient and a lesion basis 
was performed.  
In order to correlate tracer uptake with BM in-
volvement, a circular region of interest (ROI; diameter 
20 mm) was placed over the respective posterior su-
perior iliac spine and maximum (SUVmax) and mean 
standardized uptake values (SUVmean) were derived. 
Both SUV were compared to infiltration of malignant 
myeloma cells, as determined by bone marrow biop-
sy. 
Immunhistochemical quantification of L-type 
amino acid transporter 1 (LAT1)-expression 
In 15/43 patients, imaging results could be 
compared with histologic LAT1 expression of biopsy 
samples from the iliac crest. After deparaffinization 
and rehydration, the slides were placed in a pressure 
cooker in 0.01M citrate buffer (pH 7.0) and were 
heated for 7 min. Incubation with anti-CD98 antibody 
(Santa Cruz) was carried out at room temperature for 
1 hour. Detection was performed with DAKO en vi-
sion system according to the manufacturer´s protocol. 
BM involvement was assessed as percentage of posi-
tive cells relative to total cell count (per example 40% 
of nuclear cells) in 10 high power fields (HPFs) per 
sample. To minimize selection bias due to heteroge-
neous bone marrow involvement, an average of 10 
bone marrow sections per patient were analyzed. 
Statistical analysis 
Statistical analyses were performed using PASW 
Statistics software (version 22.0; SPSS, Inc. Chicago, 
IL). Quantitative values were expressed as mean ± 




standard deviation or median and range as appropri-
ate. Comparisons of related metric measurements 
were performed using Wilcoxon-signed rank test. The 
Chi square- or Fisher exact test was conducted for 
comparison of frequency data between independent 
subgroups. For bivariant correlation analyses Spear-
man or Pearson correlation coefficients were calcu-
lated. All statistical tests were performed two-sided 
and a p-value < 0.05 was considered to indicate sta-
tistical significance. No correction for p-values was 
applied to adjust for multiple tests. 
Results 
42/43 (97.7%) patients presented with MM; one 
patient was diagnosed with solitary plasmacytoma. 
High-risk cytogenetics occurred in 18/43 (41.9%) 
subjects. Information on the degree of iliac BM infil-
tration with MM plasma cells was available for 31/43 
patients and ranged from 0 to 90% (median, 30). Se-
rum FLC ranged from 9 to 25100 mg/l (median, 337.4) 
and M gradients from 0 to 58.9 g/dl (median, 3.9) 
Patients´ characteristics are summarized in table 1 and 
supplementary table 1. 
 
 
Table 1: Patients’ characteristics 
No. Sex Age Myeloma type Disease duration (months) M gradient (g/l) FLC (mg/l) BM involvement (%) Previous therapies 
1 m 76 IgG κ PD 3.4 4440 (κ) 40 none 
2 f 64 Plasmocytoma λ PD 0 9.0 (λ) 0 none 
3 f 65 IgA κ PD 0 233 (κ) 30 none 
4 f 65 IgA κ 3 0 498 (κ) 50 CTx 
5 m 64 IgG κ 4 51.1 293 (κ) 40 CTx 
6 f 60 IgG κ 120 16.2 1237 (κ) n/a CTx, Auto-Tx 
7 m 54 IgA κ PD 41.3 11.6 (κ) 70 none 
8 f 56 IgA λ PD n/a 345 (λ) 25 none 
9 m 60 IgA λ 9 3.5 2525 (λ) 90 CTx, Auto-Tx 
10 m 82 IgA κ 55 n/a 23.0 (κ) n/a CTx, 
11 m 67 IgG λ 15 n/a 15.7 (κ) 5 CTx, Auto-Tx 
12 m 59 light chain κ 7 3.4 n/a n/a RTx 
13 m 48 IgG κ PD 58.9 48.0 (κ) n/a none 
14 m 70 IgG κ 103 23.2 8833 (κ) n/a CTx, Auto-Tx 
15 f 69 IgG κ 10 26.4 687 (κ) n/a CTx, Auto-Tx 
16 f 63 light chain κ 32 0 3079 (κ) n/a CTx, Auto-Tx 
17 f 74 IgG λ PD 31.9 337 (λ) n/a none 
18 f 64 IgA κ 6 0 27,4 (κ) 0 CTx; Auto-Tx 
19 m 56 IgA κ 32 44.7 0.5 (κ) 50 CTx, Auto-Tx 
20 f 62 IgG κ 11 24.4 254.3 (κ) 15 CTx 
21 m 63 light chain κ PD 1.9 14014 (κ) 70 none 
22 f 48 IgA λ 63 6 177.7 (λ) 3 CTx, Auto-Tx 
23 m 51 IgG κ 34 24.6 828.0 (κ) 60 CTx, Auto-Tx 
24 m 47 light chain κ PD 0 904.9 (κ) 90 none 
25 m 62 light chain λ PD 1.8 444.0 (λ) 15 none 
26 m 59 IgG κ 37 0 5.0 (κ) 0 CTx, Auto-Tx 
27 m 59 IgG κ 4 26.3 551.2 (κ) 40 CTx 
28 m 65 IgG κ 89 10.4 37.8 (κ) n/a CTx, Auto-Tx 
29 f 65 IgA κ 12 0 2387 (κ) 90 CTx, Auto-Tx 
30 f 39 IgG λ 58 31.0 97.5 (λ) n/a CTx, Auto-Tx 
31 f 68 IgG λ 31 29.8 1673 (λ) 35 CTx, Auto-Tx 
32 m 73 IgG κ 72 4.7 25100 (κ) 70 CTx, Auto-Tx 
33 m 62 IgG κ 199 13.0 14015 (κ) 20 CTx, Auto-Tx 
34 m 62 light chain λ 47 0 240.8 (λ) 5 CTx, Auto-Tx 
35 m 72 IgG λ PD 35.4 5297 (λ) 90 none 
36 f 53 light chain κ 122 0 99.0 (κ) 15 CTx, Auto-Tx 
37 m 63 light chain λ 6 0 12.4 (λ) 0 CTx 
38 f 63 IgG κ 22 47.5 1907 (κ) 30 CTx, Auto-Tx 
39 m 63 IgG κ 86 4.1 535.0 (κ) n/a CTx, Auto-Tx 
40 m 60 light chain λ 22 0 124.2 (λ) 20 CTx, Auto-Tx 
41 f 63 light chain λ 23 0 1876 (λ) 10 CTx, Auto-Tx 
42 f 49 IgA λ 72 0 30.8 (λ) 0 CTx, Auto-Tx 
43 f 40 light chain κ 39 0 50.0 (κ) n/a CTx, Auto-Tx 
m = male. f = female. Disease duration is given in months. PD = primary diagnosis. CTx = chemotherapy including novel agents, RTx = radiotherapy. Auto-Tx = autologous 
stem cell transplantation. n/a = information not available 
 
 





In PET/CT examinations with MET, MM lesions 
were detected in 39/43 subjects (90.7%). In contrast, 
FDG did not identify any focal lesions in 10 patients 
(FDG-positive lesions in 33/43 patients, 76.7%; 
p<0.05; figure 1). The case presenting with solitary 
plasmacytoma was identified by PET using both 
tracers. 
Additionally, MET identified extramedullary le-
sions in 12/43 patients (27.9%), whereas FDG rec-
orded 10/43 patients with EMD (23.3%). Lymph node 
involvement was most commonly seen (7/43 [MET] 
vs. 6/43 [FDG]), followed by manifestations in soft 
tissue (6/43 [MET] vs. 4/43 [FDG]), and lungs (2/43 
[MET] vs. 2/43 [FDG]). Regarding intramedullary 
MM, MET revealed involvement of the appendicular 
skeleton in 37/43 patients (86.0%), whereas 9 cases 
were missed with FDG (FDG-positive lesions in 28/43 
patients, 65.1%) (supplementary table 3).  
Lesion-based analysis 
Imaging with MET demonstrated more focal le-
sions than FDG in 28/43 patients (65.1%, p<0.001). In 
the remaining patients, an equal number of MM 
manifestations were detected with both tracers. Most 
of the lesions exclusively identified by MET located 
within the bone marrow compartment (28/28; 100%) 
and in the appendicular skeleton (24/28; 85.7%; figure 
2).  
MET-PET/CT detected more than 20 FL in 35/39 
patients (89.7%): 3/35 (8.6%) had >20 focal lesions 
detected, 7/35 patients (20.0%) >50 and 25/35 pa-
tients (71.4%) >100 FL. The remaining 4/39 (10.3%) 
subjects had less than 20 FL. With FDG, 16/33 (48.5%) 
subjects had less than 20 FL, 3/33 (9.1%) >20, 4/33 
(12.1%) >50 and 10/33 (30.3%) >100 FL.  
Interestingly, in the 12 patients with EMD, MET 
detected lesions which were missed by FDG (6/12 
subjects; 50%; figure 3). In numbers, FDG detected a 
total of 28 EMD foci (lymph nodes, n=17; soft tissue, 
n=9; lungs, n=2), whereas MET depicted 42 lesions in 
lymph nodes (n=23), soft tissue (n=14), and lungs 
(n=5). The lesions exclusively visualized by MET were 
lymphonodal (n=6), soft tissue (n=5) and pulmonary 




Figure 1: Display of a patient (patient #11) with a history of Ig G λ MM after autologous stem cell transplant who was referred due to still low but rising serum free light chains. 
Whereas PET/CT with FDG did not depict hypermetabolic intra- or extramedullary foci suspicious for active MM, MET demonstrated inhomogenous, focally increased tracer 
uptake of the axial (transaxial slice of thoracic vertebra Th 8, arrows) as well as appendicular skeleton (maximum intensity projection). Bone marrow biopsy confirmed low tumor 
cell burden of 5%. 





Figure 2: Display of a patient (patient #1) with newly diagnosed MM Ig G κ. FDG depicts faint to moderate uptake in the skeleton in contrast to highly intense lesions in MET, 
e.g. in the right clavicle. Multiple additional intramedullary lesions are clearly detected by MET. 
 
Figure 3: Display of a patient (patient #6) with MM Ig G κ. FDG depicts moderate uptake in the skeleton in contrast to highly intense lesions in MET (maximum intensity 
projection, upper row). Additionally, pleural extramedullary disease was exclusively detected by MET (arrows, transaxial slices, lower row). The patient deceased 5 months later. 
 
Immunohistochemical work-up for LAT1 
In 15 patients (8 subjects with newly diagnosed 
and 7 with heavily pre-treated MM), imaging results 
could be compared to immunohistological staining 
for LAT1. 13/15 samples displayed homogeneous 
strong cytoplasmic and membraneous expression of 
the transporter by all myeloma cells. No differences in 
LAT1 expression or intensity on the cell level could be 
observed between the individual specimens (figure 4). 
Correlation of imaging parameters with la-
boratory findings and cytogenetics 
MET- as well as FDG-positivity was independent 
of FLC levels and/or M gradients. The presence of 




focal intramedullary lesions in MET or FDG-PET was 
indicative for abnormal β2m and FLC levels (MET, 
p=0.006 and p=0.01, respectively; FDG, p=0.02 and 
p=0.01). A slight trend towards higher intramedullary 
SUVmax in patients with high-risk cytogenetics 
(p=0.12) was also observed for MET-PET. Semiquan-
tiative parameters (SUVmean; SUVmax) as well as pres-
ence or number of extramedullary lesions did not 
correlate with cytogenetics or pathologic changes la-
boratory values including albumin (<3.5 g/dl), creat-
inine (>1.2 mg/dl), β2m (>3.5 mg/l) or levels of free 
light chains (>100).  
Correlation of tracer uptake with bone mar-
row involvement 
In the 31 patients in whom BM infiltration was 
histologically assessed, semiquantative FDG and MET 
uptake values were highly correlated (SUVmean, 
r=0.66; SUVmax, r=0.64). Both SUVmean as well as SU-
Vmax significantly correlated with the degree of ma-
lignant plasma cell infiltration for FDG- as well as 
MET-PET (p<0.001). SUVmean (r=0.90) and SUVmax 
(r=0.88) of MET-PET demonstrated stronger correla-
tions with tumor cell burden than FDG-PET derived 
parameters (r=0.60 and r=0.58, respectively) (figure 5). 
The individual numbers for all biopsies available are 
given in supplementary table 2. 
Discussion 
This study aimed at the validation of the radio-
labeled amino acid MET as advanced radiotracer for 
functional imaging of multiple myeloma. In addition, 
a comparison to the established radiotracer FDG has 
been performed. In our cohort, MET provided more 
accurate information on both intra- as well as ex-
tramedullary disease and appeared to be superior to 
FDG in the vast majority of patients. It proved useful 
in all stages of the disease ranging from untreated to 
heavily pre-treated patients having undergone SCT. 
Due to its potential to reliably reflect MM biology by 
depicting amino acid metabolism, MET served as a 
superior readout for non-invasive determination of 
tumor burden.  
This finding is in line with previously published 
reports on the feasibility and potential diagnostic su-
periority of MET-PET/CT in comparison to FDG [12, 
14]. However, in clinical studies conducted in Japan, 
the advantage of 11C-MET was confined to intrame-
dullary lesions. In our cohort, this tracer also depicted 
more extramedullary lesions in half of patients (6/12) 
presenting with EMD. Of note, EMD was exclusively 
depicted by MET in 2 patients. 
 
 
Figure 4: Histological assessment of LAT1 expression on MM bone marrow biopsies. LAT1 expression was detected in 13/15 samples using an anti-CD98 antibody. 
Sections were counterstained with H&E. Three exemplary cases are shown with corresponding anti-CD138 staining for comparison with the degree of MM-cell bone marrow 
infiltration (patient #2, 0%; patient #20, 15%; patient #7, 70%). Magnification 200x. 





Figure 5: Correlation of radiotracer uptake with bone marrow infiltration. Assessment of iliac crest bone marrow involvement by FDG and MET-PET for a single 
patient (patient #31, transaxial fused PET/CT slices, left). Dot plots for SUVmean for all individual patients (n=31) with a strong correlation for FDG (r=0.6) and a very strong 
correlation for MET (r=0.9). 
 
Interestingly, MET-PET-positivity was inde-
pendent of presence and extent of FLC and/or M 
gradient elevation. The fact that MET-PET/CT was 
positive in EMD as well as in subjects with 
non-elevated M gradient and/or FLC suggests that 
tracer uptake might be due to increased tumor anab-
olism and might therefore reflect true tumor burden 
[15]. This notion is corroborated by the fact that MET 
uptake in the posterior superior iliac spine highly 
correlated with the degree of malignant plasma cell 
infiltration and even outperformed FDG. Of note, 
L-type amino acid transporter 1 (LAT1) as the major 
uptake mechanism of 11C-MET was highly expressed 
by all myeloma cells in almost all samples analyzed. 
This finding is in contrast to a recent study which 
reported on an association of LAT1 expression with 
proliferation and poor prognosis in newly diagnosed 
MM patients [16]. A possible explanation might be 
given be the different study populations as both 
newly diagnosed but also heavily pre-treated patients 
were enrolled in our study. Further larger studies are 
needed to fully assess the prognostic value of LAT1 
overexpression. 
Based on the data presented here, MET might 
prove a more versatile marker of disease burden, es-
pecially as it depicts both low- and high-grade mye-
loma lesions. In contrast, FDG might be limited to 
more aggressive subclones of MM and therefore 
prone to underestimation of true disease extent. 
However, more research is necessary to further in-
vestigate this finding. Additionally, the impact of 
MET positivity in MM has not been clarified yet. 
Whereas FDG has proven its prognostic value in a 
number of studies [7, 15, 17], the additional value of 
the increased sensitivity of MET has to be demon-
strated. Furthermore, no study has assessed the per-
formance of this tracer in therapy monitoring so far. A 
pilot trial investigating the performance of very early 
treatment response MET-PET in patients with MM 
would be warranted. Potential drawbacks of the 
amino acid tracer concerning reduced sensitivity 
within the liver due to high physiologic uptake can be 
neglected, given the very rare hepatic involvement in 
this disease and the broad availability of combined 
PET/CT imaging. Accumulation of the radiotracer in 
normal bone marrow could be discriminated from 
active disease in our series. Even faint BM invasion of 
5% was correctly demonstrated. However, a limita-
tion of MET for routine clinical applications might be 
the requirement for an on-site cyclotron.  
This study has several limitations. It only com-
prised a limited number of patients, thereby limiting 
the statistical power. Histopathological confirmation 
of active disease, especially MET-positive, 
FDG-negative EMD manifestations was not present in 
all lesions. However, uptake of exclusively MET-avid 
lesions was typical for MM and projected on patho-
logical substrates in CT imaging. Selection bias af-




fecting the assessment of bone marrow involvement 
due to heterogeneous involvement cannot be com-
pletely excluded (though an average number of10 
sections per patient were analysed to minimize bias). 
Concluding, our results suggest that MET is su-
perior to FDG for staging and re-staging of MM. It is 
able to detect both intra- as well as extramedullary 
MM manifestations. Additionally, tracer uptake cor-
relates with BM involvement and seems to be a more 
accurate marker of tumor biology. Further research 
investigating this tracer including its potential in early 
treatment response prediction is warranted. 
Conclusion 
In this prospective study, MET was superior to 
FDG for staging and re-staging of both intra- and ex-
tramedullary MM lesions. Tracer uptake correlates 
with BM involvement and appears to be a more ac-
curate marker of tumor biology. 
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